MEK inhibitors with combinations in different cancer treatments.

Sr. no.	Drugs	Combination	FDA approved	Indication	References
01	Trametinib	GSK2141795	In 2022	Mutant melanoma	66
02	Trametinib	Dabrafenib	In 2014	Malignant melanoma	67
03	Trametinib	Dabrafenib	In 2017	Non-small cell lung cancer (NSCLC)	68
04	Trametinib	Dabrafenib	In 2018	Anaplastic thyroid cancer (ATC)	69, 70
05	Selumetinib	Dacarbazine	—	Metastatic uveal melanoma	71
06	Cobimetinib	Vemurafenib	In 2015	Metastatic melanoma	72
07	Cobimetinib	Atezolizumab	In 2020	Metastatic colorectal cancer	73
08	Encorafenib	Binimetinib	In 2018	Malignant melanoma	74
09	Pimasertib	Gemicitabine	In 2022	Metastatic pancreatic adenocarcinoma	75